GLP-1 Drugs and Tirzepatide as Multi-Target Therapies for the Triad of Diabetes, Fatty Liver, and Heart Disease | Research

The takeaway

A review highlights GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide as promising cardioprotective agents for the interconnected triad of type 2 diabetes, fatty liver disease, and cardiovascular disease.

3-condition clinical triad
Type 2 diabetes, fatty liver disease, and cardiovascular disease frequently coexist, sharing insulin resistance as a common driver and requiring integrated treatment approaches

What the researchers found

The review establishes that type 2 diabetes, MASLD, and cardiovascular disease form a clinical triad connected by shared pathophysiology including insulin resistance, chronic inflammation, oxidative stress, and endothelial dysfunction. Under-recognized factors like gut-derived metabolites and adipose tissue dysfunction contribute to disease progression.

SGLT2 inhibitors, GLP-1 receptor agonists, and tirzepatide are identified as cardioprotective agents with potential to address multiple components of this triad simultaneously. However, the review notes gaps in translating these therapies from clinical trials to routine hepatology and cardiology practice.

Why it matters

The overlap of diabetes, fatty liver disease, and heart disease affects a huge and growing patient population. Treating these conditions separately leads to fragmented care and missed opportunities. This review makes the case that GLP-1-based therapies and tirzepatide can serve as 'metabolic multi-tools' — addressing multiple conditions simultaneously rather than requiring separate drugs for each.

How the study worked

This is a narrative review synthesizing current evidence on the shared pathophysiology of type 2 diabetes, MASLD, and cardiovascular disease. The authors examine diagnostic frameworks, therapeutic approaches including novel pharmacotherapies, and propose an integrated management model.

What this study cannot tell us

This is a narrative review without new experimental data. While it comprehensively covers the shared pathophysiology and therapeutic landscape, specific clinical outcome data for the triad population using these therapies is still emerging. Translation gaps between trial evidence and real-world clinical practice are acknowledged but not resolved.

How to read the evidence

This is a narrative review synthesizing current literature on the pathophysiology and treatment of the diabetes-MASLD-CVD triad. It draws on evidence from multiple clinical trials and mechanistic studies but does not present new data.

When this study was published

Published in 2025, this review incorporates the latest evidence on tirzepatide and GLP-1 receptor agonists for multi-system metabolic disease management.

The bigger picture

The recognition of 'cardio-hepato-metabolic' disease as an interconnected spectrum is reshaping how we think about chronic disease management. GLP-1 drugs and tirzepatide are uniquely positioned because they address metabolism, liver fat, inflammation, and cardiovascular risk through a single therapeutic class — a paradigm shift from the traditional one-drug-per-condition approach.

Questions still open

Will tirzepatide show liver-specific benefits (MASLD resolution) in addition to its proven metabolic and cardiovascular effects?
How should screening protocols be designed to identify patients with all three conditions early enough for integrated intervention?
Can GLP-1 drugs reverse the accelerated vascular aging seen in patients with the diabetes-liver-heart triad?

Common questions

Why do diabetes, fatty liver, and heart disease so often occur together?

These three conditions share a common underlying driver: insulin resistance. When the body doesn't respond properly to insulin, it leads to high blood sugar (diabetes), fat accumulation in the liver (MASLD), and damage to blood vessels (cardiovascular disease). Chronic inflammation and oxidative stress worsen all three conditions simultaneously. This is why treating one without addressing the others often falls short.

Can one medication treat all three conditions?

Emerging evidence suggests that GLP-1 receptor agonists and tirzepatide come closest to this goal. These peptide-based therapies improve blood sugar control, reduce liver fat, promote weight loss, and lower cardiovascular risk — addressing multiple components of the triad through a single medication. SGLT2 inhibitors also provide multi-system benefits. However, the authors note that translating this potential into routine clinical practice still faces challenges.

Read the original research

Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm.

Reviews in cardiovascular medicine, 26(11), 43143

View on PubMed ↗Publisher’s paper ↗

Citation

Caturano, Alfredo; Nilo, Davide; Lorenzo, Giovanni Di; Rocco, Maria; Tagliaferri, Giuseppina; Piacevole, Alessia; Donnarumma, Mariarosaria; Iadicicco, Ilaria; Moretto, Simona Maria; Acierno, Carlo; Sardu, Celestino; Russo, Vincenzo; Perrone, Marco Alfonso; Vetrano, Erica; Galiero, Raffaele; Marfella, Raffaele; Bonfrate, Leonilde; Rinaldi, Luca; Conte, Caterina; Sasso, Ferdinando Carlo. (2025). Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm.. Reviews in cardiovascular medicine, 26(11), 43143. https://doi.org/10.31083/RCM43143